



Final Appraisal Recommendation

Advice number: 0123 – February 2023

Sofosbuvir/velpatasvir (Epclusa®) 400mg/100mg film-coated tablets, 200mg/50mg film-coated tablets, 200mg/50mg coated granules in sachet and 150mg/37.5mg coated granules in sachet

Submission by Gilead Sciences Ltd

Recommendation of the All Wales Medicines Strategy Group

Sofosbuvir/velpatasvir (Epclusa®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in patients from 3 years of age to < 18 years of age, in line with the National Institute of Health and Care Excellence recommendation for the use of sofosbuvir/velpatasvir for treating chronic HCV infection in adults (TA430).

Additional note(s):

- See NICE guidance for sofosbuvir/velpatasvir (Epclusa®) for the treatment of chronic hepatitis C virus infection in adults (TA430, originally published January 2017).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4573), which includes the All Wales Toxicology and Therapeutics Centre (AWTTC) assessment form, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0123:

Sofosbuvir/velpatasvir (Epclusa®) 400mg/100mg film-coated tablets, 200mg/50mg film-coated tablets, 200mg/50mg coated granules in sachet and 150mg/37.5mg coated granules in sachet. February 2023.